Table 1. Number of patients according to the course of treatment.
Course of treatment | Infliximab | Etanercept | Adalimumab | Total |
---|---|---|---|---|
1st TNF-α inhibitor | 108 (40.1%) | 95 (35.3%) | 66 (24.5%) | 269 |
Switching | 38 (54.2%) | 26 (37.1%) | 6 (8.5%) | 70 |
2nd TNF-α inhibitor | 13 (18.5%) | 12 (17.1%) | 45 (64.2%) | 70 |
TNF, tumor necrosis factor.